These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019. Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR; Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144 [TBL] [Abstract][Full Text] [Related]
49. Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. Alsenani TA; Viviani SL; Kumar V; Taracila MA; Bethel CR; Barnes MD; Papp-Wallace KM; Shields RK; Nguyen MH; Clancy CJ; Bonomo RA; van den Akker F Antimicrob Agents Chemother; 2022 Apr; 66(4):e0241421. PubMed ID: 35341315 [TBL] [Abstract][Full Text] [Related]
50. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106 [TBL] [Abstract][Full Text] [Related]
51. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021. Lee YL; Ko WC; Hsueh PR Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423 [TBL] [Abstract][Full Text] [Related]
52. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Lee YL; Ko WC; Hsueh PR Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011 [TBL] [Abstract][Full Text] [Related]
53. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756 [TBL] [Abstract][Full Text] [Related]
57. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Le Terrier C; Nordmann P; Buchs C; Poirel L Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988 [TBL] [Abstract][Full Text] [Related]
58. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602 [TBL] [Abstract][Full Text] [Related]
60. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam. Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]